US Government As Represented by the Secretary of the Army

Albert Einstein College of Medicine

University of Toronto

Microbiotix, Inc.

John M Dye

Kartik Chandran

Sachdev Singh Sidhu

Jonathan R Lai

Julia Frei

Gang Chen

Samantha Zak

Jayne F Koellhoffer

Terry L Bowlin

Arnab Basu

John D Williams

Donald T Moir

Debra M Mills

Jay P Barbor

Zachary D Aron

Kelly N Lively

Peter J Nash

Ana I Kuehne

Jayne F Koelhoffer

Shawn B Guest

The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GP) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.

Broad spectrum inhibitors of filoviruses

The present invention addresses a need for antibodies useful for filovirus infections.

Filovirus antibody

The present invention addresses a need for improved treatments for filovirus infections. This invention provides an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region. Also provided is a method of treating and/or inhibiting a filovirus infection in a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of an antigen-binding fragment thereof. Also provided is composition comprising any of the antibodies described herein, or or an amount of an antigen-binding fragment thereof. In an embodiment, the composition comprises a pharmaceutically acceptably carrier.

Therapy for filovirus infection

The present invention addresses a need for improved treatments for Filovirus infections.

The present invention addresses a need for improved treatments for filovirus infections.

We disclose Ebola Sudan Boniface virus GP Monoclonal antibodies, epitopes recognized by these monoclonal antibodies, and the sequences of the variable regions of some of these antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutic treatment of Ebola Sudan Boniface virus infections in vitro and in vivo.

Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus

Growing community of inventors

Frederick, MD, United States of America

John M Dye